Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® HCV / Hepatitis specialty page provides HCV / hepatitis-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


HIV and NAFLD More Common Than Originally Thought
Research on nonalcoholic fatty liver disease in persons infected with HIV revealed a prevalence of the condition of about 40%, suggesting the condition may be an underappreciated comorbidity in this population.
Hepatitis C Virus Retreatment Successful with SOF/VEL/VOX in Patients With and Without HIV
A fixed-dose combination therapy (Vosevi, Gilead) was highly effective after 12 weeks in retreating direct-acting antiviral-experienced patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence.
Direct-Acting Antiviral Therapy Effective for Curing Hepatitis C in Injection Drug Users
A recent study by the Kirby Institute reported that after using direct-acting antiviral therapy 97% of participants with HCV who recently used injectable drugs achieved sustained viral response.
Hepatitis A Outbreak in West Virginia Leaves Officials Scrambling
West Virginia’s Bureau for Public Health has requested the assistance from the CDC to contain the statewide hepatitis A outbreak.
Two Genes Identified as Potential Drug Targets in Treatment of HIV
New research from Johns Hopkins reveals that 2 genes, CMPK2 and BCLG, are selectively activated in the presence of type 1 interferon.
Death Among the Homeless: New Study Sheds Light on Health Issues for Those Sleeping Rough: Public Health Watch
The results of a study published by JAMA Internal Medicine are a call to action for cities facing homelessness crises.
HCV-Infected Kidneys Can Be a Good Option for Uninfected Recipients
Small studies show good outcomes for previously uninfected recipients who receive kidneys from donors infected with hepatitis.
Direct-Acting Antiviral Combo Yields High Rates of SVR in Patients with Previous Virologic Failure
The combination of direct-acting antiviral agents glecaprevir/pibrentasvir (G/P), sofosbuvir, and ribavirin is now approved for new patient populations.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?